Vivo Capital LLC lifted its holdings in shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) by 218.4% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 843,478 shares of the company’s stock after buying an additional 578,600 shares during the period. Kiniksa Pharmaceuticals comprises about 1.5% of Vivo Capital LLC’s portfolio, making the stock its 17th biggest holding. Vivo Capital LLC’s holdings in Kiniksa Pharmaceuticals were worth $15,233,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Legal & General Group Plc acquired a new stake in Kiniksa Pharmaceuticals during the third quarter worth approximately $25,000. BNP Paribas Arbitrage SA grew its stake in Kiniksa Pharmaceuticals by 1,131.7% during the first quarter. BNP Paribas Arbitrage SA now owns 2,685 shares of the company’s stock worth $48,000 after purchasing an additional 2,467 shares during the period. JPMorgan Chase & Co. grew its stake in Kiniksa Pharmaceuticals by 73.7% during the first quarter. JPMorgan Chase & Co. now owns 2,880 shares of the company’s stock worth $52,000 after purchasing an additional 1,222 shares during the period. Citigroup Inc. grew its stake in Kiniksa Pharmaceuticals by 145.9% during the first quarter. Citigroup Inc. now owns 3,426 shares of the company’s stock worth $62,000 after purchasing an additional 2,033 shares during the period. Finally, Barclays PLC grew its stake in Kiniksa Pharmaceuticals by 25.7% during the fourth quarter. Barclays PLC now owns 3,054 shares of the company’s stock worth $86,000 after purchasing an additional 624 shares during the period. 29.76% of the stock is owned by institutional investors.

Several research analysts have issued reports on KNSA shares. Zacks Investment Research lowered Kiniksa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. Barclays started coverage on Kiniksa Pharmaceuticals in a report on Monday, March 11th. They issued an “overweight” rating and a $26.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $31.00.

NASDAQ:KNSA traded up $0.15 on Wednesday, hitting $13.35. The stock had a trading volume of 1,579 shares, compared to its average volume of 125,554. The firm has a market cap of $752.14 million and a P/E ratio of -3.85. Kiniksa Pharmaceuticals Ltd has a 52 week low of $13.04 and a 52 week high of $32.88.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.47). On average, equities research analysts expect that Kiniksa Pharmaceuticals Ltd will post -3.56 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Shares Bought by Vivo Capital LLC” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://theolympiareport.com/2019/06/12/kiniksa-pharmaceuticals-ltd-nasdaqknsa-shares-bought-by-vivo-capital-llc.html.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Read More: Why do commodities matter?

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA).

Institutional Ownership by Quarter for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.